Narrow search
Showing 1 - 10 of 1,437
Cover Image
A Review of Quality of Life in Alzheimer's Disease: Part 1: Issues in Assessing Disease Impact
Walker, Melvyn D.; Salek, Sam S.; Bayer, Antony J. - In: PharmacoEconomics 14 (1998) 5, pp. 499-530
There are numerous methods available for assessing patients with Alzheimer's disease (AD) or other forms of dementia … when assessing the impact of disease and intervention in dementia. The subjective nature of quality of life provides … and instruments that claim to measure quality of life in dementia. Literature for this review was identified by a thorough …
Persistent link: https://www.econbiz.de/10005449174
Cover Image
Functional Impairment, Healthcare Costs and the Prevalence of Institutionalisation in Patients with Alzheimer's Disease and Other Dementias
Hill, Jerrold; Fillit, Howard; Thomas, Simu K.; Chang, Sobin - In: PharmacoEconomics 24 (2006) 3, pp. 265-280
-sectional analyses of the Medicare Current Beneficiary Survey (MCBS) were performed. A nationally representative sample of Medicare … nature of these relationships has not been investigated solely in patients with dementia. The data from this study suggest a … strong relationship between functional impairment and healthcare costs, specifically in patients with dementia. Even IADL …
Persistent link: https://www.econbiz.de/10005404926
Cover Image
Economic Evaluation of Rivastigmine in Patients with Parkinson's Disease Dementia
Willan, Andrew R.; Goeree, Ron; Pullenayegum, Eleanor M.; … - In: PharmacoEconomics 24 (2006) 1, pp. 93-106
Background: The positive results of a randomised clinical trial of rivastigmine in patients with dementia associated … 3-12 mg/day in patients in whom mild to moderate dementia developed at least 2 years after they received a clinical …
Persistent link: https://www.econbiz.de/10005590328
Cover Image
Do Productivity Costs Matter?: The Impact of Including Productivity Costs on the Incremental Costs of Interventions Targeted at Depressive Disorders
Krol, Marieke; Papenburg, Joc; Koopmanschap, Marc; … - In: PharmacoEconomics 29 (2011) 7, pp. 601-619
Background:Background: When guidelines for health economic evaluations prescribe that a societal perspective should be adopted, productivity costs should be included. However, previous research suggests that, in practice, productivity costs are often neglected. This may considerably bias the...
Persistent link: https://www.econbiz.de/10011005068
Cover Image
Is There a Role for Pharmacoeconomics in Developing Countries?
Harper, Jonathan R. - In: PharmacoEconomics 29 (2011) 5, pp. 435-436
Persistent link: https://www.econbiz.de/10011005069
Cover Image
Cost Effectiveness of Treatment with New Agents in Advanced Non-Small-Cell Lung Cancer: A Systematic Review
Bongers, Mathilda L.; Coupé, Veerle M.H. Coup; Jansma, … - In: PharmacoEconomics 30 (2012) 1, pp. 17-34
In past decades, studies focusing on new chemotherapeutic agents for patients with inoperable non-small-cell lung cancer have reported only modest gains in survival. These health gains are achieved at considerable cost, but economic evidence is lacking on superiority of one agent in terms of...
Persistent link: https://www.econbiz.de/10011005070
Cover Image
Cost of Illness of Cystic Fibrosis in Germany: Results from a Large Cystic Fibrosis Centre
Heimeshoff, Mareike; Hollmeyer, Helge; Schreyogg, Jonas … - In: PharmacoEconomics 30 (2012) 9, pp. 763-777
Background:Background: Cystic fibrosis (CF) is the most common life-shortening genetic disorder among Whites worldwide. Because many of these patients experience chronic endobronchial colonization and have to take antibiotics and be treated as inpatients, societal costs of CF may be high. As the...
Persistent link: https://www.econbiz.de/10011005071
Cover Image
Impact of Transformation of Negative Values and Regression Models on Differences Between the UK and US EQ-5D Time Trade-Off Value Sets
Augestad, Liv Ariane; Rand-Hendriksen, Kim; … - In: PharmacoEconomics 30 (2012) 12, pp. 1203-1214
Background:Background: National EQ-5D value sets are developed because preferences for health may vary in different populations. UK values are lower than US values for most of the 243 possible EQ-5D health states. Although similar protocols were used for data collection, analytic choices...
Persistent link: https://www.econbiz.de/10011005072
Cover Image
Impact of Treatment Success on Health Service Use and Cost in Depression: Longitudinal Database Analysis
Byford, Sarah; Barrett, Barbara; Despiégel, Nicolas … - In: PharmacoEconomics 29 (2011) 2, pp. 157-170
Background: Research has consistently demonstrated a relationship between depression and increased levels of health service use over the short term. However, much less is known about how this relationship is influenced by the success, or otherwise, of depression management strategies, and the...
Persistent link: https://www.econbiz.de/10011005073
Cover Image
Cost Effectiveness of Denosumab Compared with Oral Bisphosphonates in the Treatment of Post-Menopausal Osteoporotic Women in Belgium
Hiligsmann, Mickal; Reginster, Jean-Yves - In: PharmacoEconomics 29 (2011) 10, pp. 895-911
Background: Denosumab has recently been shown to be well tolerated, to increase bone mineral density (BMD) and to significantly reduce the risk of hip, vertebral and non-vertebral fractures in the FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis every 6 Months) trial. It is...
Persistent link: https://www.econbiz.de/10011005074